Navigation Links
Gene Found Activated in 70% of Prostate Cancer Cases, George Washington University Medical Center Scientists Report
Date:10/24/2008

DRS. PATRICIA BERG AND ARNOLD SCHWARTZ LED TEAM, Article in Modern Pathology set for print publication January 2009

BERG HAD ALSO DISCOVERED SAME GENE'S ACTIVATION IN MAJORITY OF BREAST CANCER CASES

WASHINGTON, Oct. 24 /PRNewswire-USNewswire/ -- A gene has been found activated in 70% of prostate cancer tumors, the same gene that has been discovered activated in a majority of breast cancer cases, report scientists at the George Washington University Medical Center led by Dr. Patricia Berg, who discovered and cloned the gene, and Dr. Arnold Schwartz. Berg is Professor of Molecular Biology and Biochemistry and directs a laboratory at George Washington University Medical Center in Washington, DC, and Schwartz is Professor of Pathology and practicing clinician at GWUMC.

In the January, 2009 print issue of Modern Pathology, a journal of the Nature Publishing Group, the team of researchers led by Berg and Schwartz will report that "Significant BP1 immunoreactivity was identified in approximately 70% of prostatic adenocarcinomas, whether the analysis was performed on tissue sections (50 cases) or tissue microarray platforms (123 cases)." The findings compare to "less than 5%" BP1 activity in normal cells. The researchers conclude that "These findings suggest that BP1 is an important upstream factor in the carcinogenic pathway of prostate cancer and that the expression of BP1 may reflect or directly contribute to tumor progression and/or invasion."

In addition to Berg and Schwartz, the team of authors includes Drs. Yan-Gao Man, Department of Gynecologic and Breast Pathology, The Armed Forces Institute of Pathology, Washington DC; M Katayoon Rezaei, Department of Pathology, The George Washington University Medical Center, Washington DC; and Samuel J Simmens, Department of Biostatistics, The George Washington University Medical Center, Washington DC.

Berg had previously published and reported, and the authors cite in the current article, that BP1 is activated in a majority of breast cancer (80%) and acute myeloid leukemia (63%) cases. The authors say, "Our current and past findings suggest that BP1 may be an important regulatory factor in the oncogenic pathway of several malignancies including prostate cancer." Berg stated today, "BP1 is a new, potentially significant target for therapy. It could be an important new diagnostic marker for prostate cancer and the other cancers in which it is expressed."

Prostate cancer is the leading cancer among men. The National Cancer Institute estimates 186,320 new cases and 28,660 deaths from prostate cancer in the U.S. in 2008.

The article is titled, "BP1, a homeoprotein, is significantly expressed in prostate adenocarcinoma and is concordant with prostatic intraepithelial neoplasia." The article is also available as "advance online publication" (Citation: Modern Pathology advance online publication 17 October 2008; doi: 10.1038/modpathol.2008.168).

Link to abstract: http://www.nature.com/doifinder/10.1038/modpathol.2008.168.

CONTACT: Dr. Berg/GWUMC: Robert Weiner Associates, +1-301-283-0821, +1-202-329-1700, Modern Pathology: Marsha Cline, +1-317-274-2476


'/>"/>
SOURCE Dr. Patricia Berg of GWUMC/Robert Weiner Associates
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Local Research Foundation Achieves Milestone in Fight Against Cancer
2. Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinsons Disease
3. New Genes Found for Inflammatory Bowel Disease in Children
4. SF1126, Semafores PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines
5. Gene That Causes Childhood Cancer Neuroblastoma Is Found
6. Alzheimers Foundation of America Survey: Americans With Memory Concerns Fall Short of Talking to Doctors
7. Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinsons Disease Under Rapid Response Innovation Awards 2008
8. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
9. Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinsons Disease
10. PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124
11. Childrens Brain Tumor Foundations Tissue Bank Consortium May Solve Dire Problem in Pediatric Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017  CVS Pharmacy, the retail division ... new store design to enhance the retail customer ... health-focused products and expanded beauty selections paired with ... discover new offerings. Together with its innovative digital ... the customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... Research and Markets has announced the ... Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies ... ... was valued at US$ 7,167.6 Mn in 2015, and is ... a CAGR of 5.6% from 2016 to 2024. ...
(Date:4/20/2017)... Research and Markets has announced the ... Market Analysis By Service (Manufacturing, Research), By Country, (Brazil, Mexico, ... report to their offering. ... The Latin American pharmaceutical contract manufacturing services market ... Low drug registration cost in Latin American countries and ...
Breaking Medicine Technology:
(Date:4/25/2017)... Amherst, NY (PRWEB) , ... April 25, 2017 , ... ... much stress at work can also decrease overall productivity and performance in the workplace. ... their employees. , During the last few weeks of April, Clearview Resolution Services will ...
(Date:4/25/2017)... ... April 25, 2017 , ... The doctors at Wall Centre ... live with dental fear and require sedation to receive dental care. The doctors offer ... various procedures, from hygienic cleanings to oral surgery, at their dental office in Vancouver. ...
(Date:4/25/2017)... ... 25, 2017 , ... As pharmaceutical companies are held to ... process innovation in drug formulation and manufacturing. CoreRx offers its clients more ... in support of their development and manufacturing goals. , The company was ...
(Date:4/25/2017)... ... ... Buyers and sellers in the thriving multi-billion dollar cannabis marketplace – from ... be heartened by the industry’s current surge. But another thing that unifies them is ... At last they can simply, safely and effectively end their aroma anguish thanks to ...
(Date:4/25/2017)... ... 25, 2017 , ... Emergency Physician and Distinguished Professor of Emergency Medicine Bentley ... in Writing, set to publish in summer 2017. , Dr. Bobrow, MD, FACEP, ... Arizona College of Medicine. He also serves as Medical Director for the Bureau of ...
Breaking Medicine News(10 mins):